

23 December 2005

To all interested parties

Notification of changes relating to Zoladex

PHARMAC's Chief Executive has approved an agreement with AstraZeneca regarding Zoladex.

The agreement will mean that the price of Zoladex 10.8 mg will be reduced by 20% from 1 July 2006 to the level of the reference price for the Gonadotrophin Releasing Hormone (GnRH) subgroup. A further reduction in price for both the 10.8 mg and 3.6 mg injections will occur on 1 July 2007. AstraZeneca has withdrawn its discontinuation of Zoladex, and both strengths will continue to be fully subsidised under Special Authority from 1 January 2006.

Chemical	Presentation	Product	Pack size	Price and subsidy
<i>From 1 January 2006</i>				
goserelin	Inj, 3.6 mg	Zoladex	1	\$277.00
goserelin	Inj, 10.8 mg	Zoladex	1	\$739.60
<i>From 1 July 2006</i>				
goserelin	Inj, 3.6 mg	Zoladex	1	\$277.00
goserelin	Inj, 10.8 mg	Zoladex	1	\$591.68
<i>From 1 July 2007</i>				
goserelin	Inj, 3.6 mg	Zoladex	1	\$221.60
goserelin	Inj, 10.8 mg	Zoladex	1	\$554.70

All prices and subsidies are ex-manufacturer, exclusive of GST

The agreement provides for a secure supply of both strengths of Zoladex until at least December 2008, and provides AstraZeneca with protection against delisting or subsidy reduction of Zoladex until this same date.

If you have any questions regarding this change, please contact PHARMAC on 0800 66 00 50 (9am-4pm weekdays).

Yours sincerely



Tommy Wilkinson
Therapeutic Group Manager Intern